PetMed Express

PetMed Express, Inc. engages in the provision of markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The firm markets its products through national television, online and direct mail or print advertising campaigns. The company was founded in January 1996 and is headquartered in Delray Beach, FL.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

PetMed Express reports Q1 2023 earnings, anticipates growth from PetCareRx acquisition

PetMed Express faced sales decline, but the acquisition of PetCareRx and strong new customer growth provide optimism for future profitability. Financial stability, operational focus, and strategic partnerships position the company for long-term success.

PetMed Express reports Q3 sales dip but gains new customers

PetMed Express navigated challenges with a 3% decrease in YoY sales but gained 9% more net new customers. The company's focus on pet health expertise and expanding offerings positions it for future growth.
Despite advertising spending increases, PetMed maintains a strong balance sheet with over $102 million in unrestricted cash. Management's confidence in future prospects and innovative strategies bode well for the company's growth trajectory.

PetMed Express reports sales decline, eyes growth from acquisitions

PetMed Express focused on pet wellness, recent acquisitions, and strategic investments in telemedicine and pet insurance.
Despite sales decline in fiscal year 2023, the company aims for growth from the PetCareRx acquisition in 2024.
Challenges in over-the-counter medication sales and a net loss in Q4 were offset by a strong cash position and strategic focus on growth.

PetMed Express reports record revenue growth and expands pet insurance

PetMed Express (PETS) demonstrated strong financial performance in Q1 2024, with record-setting revenue growth and a focus on sustainable long-term growth.
The company's strategic initiatives, including the integration of the PetCareRx acquisition and expansion into the pet insurance market, position it for future success.
While facing challenges in a competitive market, PetMed Express has opportunities to solidify its market leadership in pet wellness and healthcare through customer-centric strategies.

PetMed Express reports Q2 growth, shifts focus to tech investments

PetMed Express (PETS) demonstrated solid financial performance in Q2 2024 with revenue growth and operational enhancements. While facing challenges in customer retention and market conditions, the company is strategically investing in technology and growth initiatives. With a focus on long-term sustainability and innovation, PetMed Express aims to drive growth and shareholder value in the pet health sector.

PetMed Express reports strong sales growth amidst accounting challenges

PetMed Express shows resilience in sales growth despite accounting challenges.
The company's focus on transparency and customer programs is a key strength.
Challenges include the need for a financial restatement and maintaining investor confidence.
Opportunities lie in strengthening internal controls and driving growth through acquisitions.

PetMed Express reports sales growth, invests in tech for future

PetMed Express (PETS) reported positive sales growth in Q4 2024 driven by the PetCareRx acquisition, despite a net loss due to acquisition-related expenses.
The company's customer-centric focus, strategic investments in technology, and strong leadership team additions position it well for future growth.
Challenges include managing expenses post-acquisition and navigating competitive pressures in the pet medications market, while opportunities exist in market expansion and operational enhancements.

PetMed Express (PETS) reports Q1 challenges but sees early improvements

PetMed Express (PETS) navigated a transition quarter with a focus on growth and profitability. Despite a sales decline and margin decrease, early signs of improvement were observed. The company emphasized optimizing cost structure, enhancing customer growth strategies, and implementing technology improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PetMed Express, Inc. provides markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, and generic substitutes. The company was founded in January 1996 and is headquartered in Delray Beach, FL.

Artisan Partners Asset Management

Broadmark Realty Capital Inc.

Blackstone Mortgage Trust

Ladder Capital

Luminex

Medifast

Public Service Enterprise Group

Pfizer

Charles Schwab

Nate Pile — the editor of growth stock advisory Nate's Notes has just released the first issue of a new advisory service focused on retirement investing, The Little River Investment Guide. The advisor reviews the initial 12 stocks that will make up his income-generating retirement portfolio.

12 Stocks For An Income Generating Retirement Portfolio

PetMed Express (PETS) earnings for the online pet pharmacy company's fiscal first quarter of 2020 have PETS stock falling on Monday.

PetMed Express Earnings: PETS Stock Sinks 16% Despite Strong Q1 Results

The pet pharmacy delivered solid revenue and earnings growth. But its bottom-line improvement wasn't quite good enough to impress analysts.

What's Behind PetMed Express' Q1 Earnings Miss

PetMed Express, Inc. (PETS) CEO Mendo Akdag on Q1 2020 Results - Earnings Call Transcript

Investors were disappointed by an earnings miss of one penny.

Why PetMed Express Shares Are Sinking Today

Shares of PetMed Express Inc. PETS, -3.10% slipped 1.2% in Monday premarket trading after the pet pharmacy reported first-quarter earnings that missed expectations.

PetMed Express stock slips after earnings miss

20% Increase in 1st Quarter Sales    47% Increase in 1st Quarter Diluted Earnings per Share    29% Increase in 1st Quarter New Order Sales

PetMed Express d/b/a 1-800-PetMeds Announces Its Record First Quarter Financial Results

DELRAY BEACH, Fla., July  13, 2020  (GLOBE NEWSWIRE) -- PetMed Express, Inc. (NASDAQ: PETS) will announce its financial results for the quarter ended June 30, 2020 on Monday, July 20, 2020 at 8:00 A.M. Eastern Time, then at 8:30 A.M. Eastern Time, Menderes Akdag, the Company’s Chief Executive Officer and President, will host a conference call to review the financial results.

PetMed Express d/b/a 1-800-PetMeds to Announce Its First Quarter Financial Results on July 20, 2020

American Tower

American Water Works

Baxter

Cardinal Health

Chubb

Cogent Communications Holdings

Costco

Expeditors International of Washington

Johnson & Johnson

Microchip Technology

Medtronic

Nasdaq

Newmont Mining

Northrop Grumman

PepsiCo

Procter & Gamble

Pool

Power Integrations

Xilinx

These 21 stocks were doling out dividend increases as the coronavirus crisis accelerated – and as many stocks were cutting or outright suspending their payouts.

21 Dividend Increases Announced During the COVID Crisis

Merck

Phibro Animal Health

Spending on pet health continues to climb. Investors should consider buying PetMed Express, Phibro Animal Health, and Merck & Co.

3 Pet Med Stocks That Offer Growth and a Nice Dividend

CV-19 has accelerated the ongoing trend of e-commerce animal medication fulfillment.

PetMed Express: Tailwinds Are Pushing Pet Medicine Into The Future

But acquiring new customers remains difficult.

PetMed Express Earnings Seem Immune to Coronavirus

The company benefited from a migration to online sales by consumers during the coronavirus-affected quarter.

PetMed Express Falls Nearly 3% Despite Q4 Beats, Dividend Raise

PetMed Express, Inc. (PETS) CEO Mendo Akdag on Q4 2019 Results - Earnings Call Transcript

Shares of PetMed Express (NASDAQ:PETS) rose 3.5% in pre-market trading after the company reported Q4 results.

PetMed Express: Q4 Earnings Insights

PetMed Express Is Booming And Could See Long-Lasting Profits

A Relative Strength Rating upgrade for PetMed Express shows improving technical performance.
The post PetMed Express Shows Market Leadership With Jump To 93 RS Rating appeared first on Investor's Business Daily.

PetMed Express Shows Market Leadership With Jump To 93 RS Rating

Astronics

B&G Foods

Elastic N.V

Freshpet

Inspire Medical Systems Inc

Northern Oil and Gas

While the large caps get all the attention, lately, this is more of a negative development than a positive one

8 Stellar Small-Cap Stocks to Buy That Are in Major Industries

A Relative Strength Rating upgrade for PetMed Express shows improving technical performance.

Stocks Showing Market Leadership: PetMed Express Earns 91 RS Rating

A Relative Strength Rating upgrade for PetMed Express shows improving technical performance. Will it continue?

PetMed Express Getting Closer To Key Technical Benchmark

The Pet Pharmacy is the source of its high gross margins and that is coming under attack from Chewy and Walmart.

PetMed Express: Caught In The Crossfire And Cracks Showing - Sell

The online pet pharmacy topped analysts' earnings estimates but missed on the top line.

How PetMed Express Dropped the Ball With Its Q3 Results

PetMed Express, Inc (PETS) CEO Mendo Akdag on Q3 2019 Results - Earnings Call Transcript

News for PetMed Express Stock (PETS)